257 related articles for article (PubMed ID: 19648603)
1. Sorafenib and sunitinib.
Kim A; Balis FM; Widemann BC
Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
[No Abstract] [Full Text] [Related]
2. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
3. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
4. Kidney cancer: Does hypothyroidism predict clinical outcome?
Rini B
Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
[No Abstract] [Full Text] [Related]
5. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
6. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
[No Abstract] [Full Text] [Related]
7. Current and future management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
[No Abstract] [Full Text] [Related]
8. [New drugs; sunitinib and sorafenib].
Bellersen L
Ned Tijdschr Geneeskd; 2008 Feb; 152(8):469-70; author reply 470. PubMed ID: 18363211
[No Abstract] [Full Text] [Related]
9. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
[No Abstract] [Full Text] [Related]
10. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
11. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Mego M; Reckova M; Obertova J; Sycova-Mila Z; Brozmanova K; Mardiak J
Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
[No Abstract] [Full Text] [Related]
12. [New drugs; sunitinib and sorafenib].
van Bronswijk H; Dubois EA; Osanto S; Cohen AF
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
[TBL] [Abstract][Full Text] [Related]
13. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
14. Therapy for metastatic RCC--questions remain.
Breau RH; Leibovich BC
Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
[No Abstract] [Full Text] [Related]
15. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
16. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Lacouture ME; Reilly LM; Gerami P; Guitart J
Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
[TBL] [Abstract][Full Text] [Related]
17. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
[TBL] [Abstract][Full Text] [Related]
18. [New therapeutic regimes in metastasic renal-cell carcinoma].
Bierer S; Hertle L; Nitschmann S
Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
[No Abstract] [Full Text] [Related]
19. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Di Fiore F; Rigal O; Ménager C; Michel P; Pfister C
Br J Cancer; 2011 Dec; 105(12):1811-3. PubMed ID: 22095228
[TBL] [Abstract][Full Text] [Related]
20. Risk of bleeding not increased by sorafenib or sunitinib.
Minor DR
Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
